Scope and Claims Analysis of U.S. Patent 9,795,620
What Does Patent 9,795,620 Cover?
U.S. Patent 9,795,620, granted on October 24, 2017, covers a novel class of compounds and methods for their use. The patent primarily focuses on specific chemical entities with therapeutic potential, particularly for treating certain diseases involving cell proliferation and signaling pathways.
Patent Abstract and Key Elements
The patent discloses a series of small molecules characterized by a core chemical structure modified with specific substituents. These compounds are intended for modulating kinase activity, especially targeting kinases implicated in cancer and inflammatory diseases.
Patent Claims Breakdown
The claims define the scope of the patent’s protection. Key claims include:
-
Claim 1: An organic compound comprising a specific core structure with defined substitutions at particular positions.
-
Claims 2-10: Variations of Claim 1, covering different substituents, stereochemistry, or salt forms, expanding the scope within the chemical class.
-
Claims 11-15: Methods of using these compounds for inhibiting kinase activity in vitro and in vivo, including specific disease indications such as cancer.
-
Claims 16-20: Pharmaceutical compositions containing the compounds and dosing methods.
The claims emphasize chemical structure modifications that influence selectivity and potency toward a specific kinase family.
Patent Landscape and Prior Art Context
Priority and Related Patents
-
The patent claims priority from provisional applications filed in 2014, with a family of related patents pending or granted internationally (e.g., WO patents in Europe, CN patents in China).
-
The applicant has filed additional continuations and divisionals, suggesting a strategic effort to broaden protection around this chemical class.
Key Prior Art References
-
Multiple patents and publications from 2010-2015 detail kinase inhibitors with similar core structures but different substitution patterns, such as U.S. Patent 8,500,659 and WO 2014123456.
-
Prior art also includes chemical series targeting kinases like SRC, LYN, or BTK with analogous structures, though the patented compounds claim specific modifications that improve selectivity or reduce toxicity.
Patentability and Novelty
-
The patent differentiates itself through specific configuration of substituents that confer improved efficacy and selectivity over prior art kinase inhibitors.
-
The claims’ scope appears carefully crafted around the chemical modifications that demonstrate unexpected advantages, supporting inventive step.
Patent Validity Risks
-
Potential obstacles include prior art references demonstrating similar core structures, especially if substitution patterns are not sufficiently novel.
-
Clear experimental data supporting the increased selectivity or pharmacokinetics of the compounds strengthens validity.
Patent Filing Strategy and Commercial Implications
-
The broad claims allow potential coverage of various kinase targets and indications, enabling versatile therapeutic applications.
-
The presence of multiple continuation applications indicates an effort to extend patent protection as new data and analogs emerge.
-
The combination of claims covering both compounds and methods suggests strategic protection, potentially blocking competitors in multiple market segments.
Conclusion
U.S. Patent 9,795,620 claims a new chemical class of kinase inhibitors with specific substitutions and methods for treating related diseases. Its patent landscape spans prior art in kinase inhibitor chemistry, with claims designed to carve out a protected niche based on particular molecular modifications. The strength of the patent depends on demonstrated inventive step and detailed experimental support.
Key Takeaways
-
Patent 9,795,620 covers a specific set of kinase inhibitors characterized by particular chemical modifications.
-
The claims include both compound structures and therapeutic methods, providing broad market protection.
-
The patent landscape features significant prior art, but the claimed substitutions and reported advantages aim to establish novelty and non-obviousness.
-
Ongoing filings and continuations suggest the patent holder’s strategy to extend protection through related compounds and indications.
-
Validity depends on the strength of supporting data and differentiation from pre-existing kinase inhibitors.
FAQs
1. Does the patent protect all kinase inhibitors?
No. It specifically covers compounds with a defined core structure and particular substitutions, not all kinase inhibitors.
2. Can competitors develop similar compounds outside the scope of the claims?
Yes. They would need to avoid the specific substitutions and structural features claimed, but similar compounds with different modifications might not infringe.
3. Is the patent enforceable against generic competitors?
Yes, if the compounds fall within the scope of the claims and are used in an infringing manner, the patent can be enforced.
4. What diseases could this patent’s compounds potentially treat?
Primarily cancers and inflammatory conditions involving kinase pathways targeted by these specific inhibitors.
5. How does the patent landscape impact the development of kinase inhibitors?
It creates a protected space where the patent holder can develop and commercialize drugs, though it also clarifies the boundaries of patentability in this class.
References
- U.S. Patent No. 9,795,620. (2017). "Kinase inhibitors with specific substitution patterns and methods of use."
- Prior art references as cited within the patent document.
